Journal profile · Immunology
Cellular & Molecular Immunology
ISSN 1672-7681 · eISSN 2042-0226 · Springer Nature · PEOPLES R CHINA · Bimonthly · Founded 2008
Cellular & Molecular Immunology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 23.83; hybrid open access; APC about USD 5,190; median 154 days to acceptance (90 articles, last 24 months); 128 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cellular & Molecular Immunology is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Immune Cell Function and Interaction, T-cell and B-cell Immunology and Immunotherapy and Immune Responses, together about 42.7% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Covering both basic immunology research and clinical applications, Cellular & Molecular Immunology (CMI) provides the latest information and advancements in our understanding of the immunological response of the host, both in vitro and in vivo. Please go to Aims and scope page for more details.
From the journal's Aims & Scope
Research area (LetPub): Immunology
Editor-in-chief Xuetao CaoPublisher website
Editorial board by country: 2 in mainland China (about 50%); most named Mainland China 2, United States 2 (4 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune Cell Function and InteractionImmunology and Microbiology20.3%
- T-cell and B-cell ImmunologyImmunology and Microbiology12.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology9.5%
- Immune Response and InflammationImmunology and Microbiology5.8%
- Immune cells in cancerImmunology and Microbiology5.2%
- interferon and immune responsesImmunology and Microbiology4.5%
- IL-33, ST2, and ILC PathwaysImmunology and Microbiology4.2%
- CAR-T cell therapy researchMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPMCPubMedCASPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 23.83LetPub ·
- Impact factor (publisher) 2025
- 23.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 27.6Publisher website ·
- CiteScore 2026-06
- 33.9LetPub ·
- SJR 2026-06
- 7.02LetPub ·
- SNIP 2026-06
- 3.78LetPub ·
- h-index
- 64LetPub ·
- h-index
- 176OpenAlex ·
- i10-index
- 1,670OpenAlex ·
- 2-year mean citedness
- 21.68OpenAlex ·
- Self-citation rate
- 1.3%LetPub ·
- Share of gold OA articles
- 54.71%LetPub ·
Volume
- Articles per year
- 90LetPub ·
- Downloads per year (publisher) 2025
- 3,503,409Publisher website ·
Articles by year OpenAlex count · 2,352 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 92 | 81 | 221 |
| 2025 | 128 | 116 | 3,175 |
| 2024 | 128 | 128 | 4,149 |
| 2023 | 157 | 157 | 7,620 |
| 2022 | 155 | 155 | 8,455 |
| 2021 | 210 | 210 | 18,628 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
154 daysMedian, submission to acceptance · P25–P75 80 days – 219 days
- Acceptance to online
- median 24 days (90 articles)
- Submission to online
- median 182 days
- Sample
- 90 articles with submission and acceptance dates (251 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,190 / EUR 4,090 / GBP 3,490 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- PEOPLES R CHINA
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2008
- ISSN
- 1672-7681
- Electronic ISSN
- 2042-0226
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cellular & Molecular Immunology
What CAS zone is Cellular & Molecular Immunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cellular & Molecular Immunology is in Zone 1 of Medicine, and in Zone 1 of the minor category Immunology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cellular & Molecular Immunology?
The latest impact factor listed by LetPub is 23.83; CiteScore 33.9, h-index 176.
How long does peer review take at Cellular & Molecular Immunology?
Based on the dates recorded on 90 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 154 days (interquartile range 80–219 days); authors report an average review time of about 1 month. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cellular & Molecular Immunology based?
Of the 4 board members whose country the journal's board page names, 2 (about 50%) are in mainland China; the countries named most often are Mainland China (2) and United States (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Cellular & Molecular Immunology?
According to LetPub and DOAJ records, Cellular & Molecular Immunology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PMC, PubMed and CAS; that list has not been checked against each database.
Is Cellular & Molecular Immunology open access, and what is the APC?
Cellular & Molecular Immunology is a hybrid journal. For open-access publication: APC about USD 5,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .